Sino Biopharmaceutical Limited (FRA:SMZ1)

Germany flag Germany · Delayed Price · Currency is EUR
0.4634
+0.0237 (5.39%)
At close: May 16, 2025, 10:00 PM CET
29.88%
Market Cap 8.32B
Revenue (ttm) 3.82B
Net Income (ttm) 463.14M
Shares Out n/a
EPS (ttm) 0.03
PE Ratio 17.97
Forward PE 20.21
Dividend 0.01 (1.62%)
Ex-Dividend Date Jun 16, 2025
Volume 6,776
Average Volume 30,922
Open 0.4556
Previous Close 0.4397
Day's Range 0.4523 - 0.4634
52-Week Range 0.3001 - 0.4799
Beta n/a
RSI 54.21
Earnings Date May 16, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. It offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under An... [Read more]

Industry Pharmaceutical Preparations
Founded 2000
Employees 24,379
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SMZ1
Full Company Profile

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.